SILENCE THERAP. SP.ADR/1 (XRP2) - Total Liabilities
Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has total liabilities worth €69.14 Million EUR (≈ $80.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of SILENCE THERAP. SP.ADR/1 to see how much of total assets are deployed in long-term investments.
SILENCE THERAP. SP.ADR/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how SILENCE THERAP. SP.ADR/1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SILENCE THERAP. SP.ADR/1 total assets.
SILENCE THERAP. SP.ADR/1 Competitors by Total Liabilities
The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
Poland | zł2.77 Billion |
|
P.C.B Tec
TA:PCBT
|
Israel | ILA72.52 Million |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
USA | $87.84K |
|
888 Holdings plc
F:C8V
|
Germany | €2.77 Billion |
|
Roman DBDR Acquisition Corp. II Ordinary shares
NASDAQ:DRDB
|
USA | $1.10 Million |
|
RoadMain T Co Ltd
SHG:603860
|
China | CN¥149.40 Million |
|
Lanzhou Huanghe Enterprise Co Ltd
SHE:000929
|
China | CN¥321.56 Million |
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
China | $4.72 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SILENCE THERAP. SP.ADR/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XRP2 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SILENCE THERAP. SP.ADR/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual total liabilities of SILENCE THERAP. SP.ADR/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €69.14 Million ≈ $80.83 Million |
+0.77% |
| 2024-12-31 | €68.61 Million ≈ $80.21 Million |
-29.60% |
| 2023-12-31 | €97.45 Million ≈ $113.94 Million |
-5.74% |
| 2022-12-31 | €103.38 Million ≈ $120.87 Million |
-12.62% |
| 2021-12-31 | €118.32 Million ≈ $138.33 Million |
-- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more